| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lunai Bioworks Inc.
$2.3
-0.03 (-1.29%)
Market Cap
10.43 M
EPS
-28.29
P/E Ratio
-
Value Trade
56.41 K
5.02 %
Week
7.98 %
1 Month
-46.51 %
3 Month
-21.23 %
6 Month
-99.27 %
5 Year
-99.53 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
13.73 K
52 Week Range
1.21 - 13.28
% held by Insiders
44.4 %
% held by Institutions
3.5 %
Enterprise Value
7.39 M
Total Shares
4.53 M
Short %
6.92 %
Float Shares
24.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lunai Bioworks Inc.
93Total events
6Upcoming
25Tier-1 (high impact)
2016 – 2027Coverage
Upcoming catalysts 2
TBD
T1Emergency Use Authorization
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
▲Preclinical PoCPreclinical
Subscribe to view catalyst details
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
LNAI Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LNAI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LNAI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LNAILunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
Lunai Bioworks has showcased a successful AI-driven approach for screening chemical risks associated with generative AI. Their subsidiary, BioSymetrics, conducted a study that achieved a 5.1-fold enrichment in identifying acetylcholinesterase (AChE) active compounds. This development aims to enhance biosecurity and chemical safety while addressing dual-use risks in AI applications. Lunai is open to collaborations with major AI developers to further this initiative.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint
Lunai Bioworks issued a correction to its previous press release from August 27, 2026, regarding the naming of six broker-dealers in a naked short selling suit. The correction solely updates a hyperlink to the Second Amended Complaint, with no other content changes. The company confirms that all other statements in the original release remain accurate.
Read more →LNAILunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit
Lunai Bioworks has filed a Second Amended Complaint in the U.S. District Court, naming six broker-dealers and two principals in a lawsuit alleging securities fraud and market manipulation. This legal action highlights the company's ongoing litigation strategy and the potential complexities involved in civil litigation. The outcome remains uncertain as the case progresses.
Read more →LNAILunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
Lunai Bioworks has entered a Master Collaboration Agreement with BrainStorm Therapeutics to enhance Parkinson's disease treatment through AI-driven patient stratification and human brain organoid models. The collaboration aims to identify clinically distinct Parkinson's subtypes and develop biomarkers and therapeutic targets. An initial data readout is anticipated in the first half of 2027.
Read more →LNAI▲ +6.7%on this newsshared move
Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit
Lunai Bioworks has filed an amended complaint in Delaware against ten defendants for alleged naked short selling, claiming over 81% of its shares faced delivery failures. The complaint highlights instances of excessive trading volume and seeks treble damages under federal law. Lunai's leadership emphasizes accountability and ongoing investigations into trading activities.
Read more →LNAI▲ +40.6%on this news
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
Lunai Bioworks has made significant strides in establishing itself as a leader in biotechnology, particularly in biodefense and precision neurology. The company secured a multi-year defense contract and formed the Pathfinder Consortium with prestigious institutions. Additionally, it is actively addressing market manipulation through legal action to protect shareholder value. The CEO emphasizes the company's commitment to advancing its platforms and creating long-term value.
Read more →LNAI▲ +40.6%on this newsshared move
LUNAI BIOWORKS
Lunai Bioworks has made significant strides by securing a revenue-generating defense contract with the U.S. government and advancing its precision neurology pipeline through various collaborations. The company formed the Pathfinder Consortium to enhance its biodefense capabilities and received funding for research initiatives in neurological diseases. Lunai has taken legal action against market manipulation that may have affected its stock price, emphasizing its commitment to shareholder value. The company aims to expand its platforms and validate its technology in both drug development and national security.
Read more →LNAI▲ +16%on this news
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
Lunai Bioworks and BrainStorm Therapeutics have announced a strategic collaboration to discover and advance novel therapeutic targets for neurological diseases, supported by a grant from the LouLou Foundation. The partnership combines AI-driven discovery with human-derived organoid systems, aiming to improve translational success and address unmet medical needs in conditions like Parkinson's disease and rare genetic epilepsies. Initial efforts will focus on identifying biomarkers and developing high-confidence therapeutic programs for pharmaceutical partnering.
Read more →LNAIFederal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock
A U.S. District Court has allowed Lunai Bioworks to expedite discovery to identify 'John Doe' naked short sellers. This decision follows allegations of market manipulation affecting Lunai's stock price. The company aims to hold these sellers accountable for damages. Lunai's legal team plans to pursue further action based on the findings from this discovery.
Read more →LNAI▼ -10.2%on this newsshared move
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
Lunai Bioworks, Inc. has announced a reverse stock split at a ratio of 1-for-8, effective May 22, 2026. This action, approved by stockholders, aims to boost the share price to meet Nasdaq listing requirements. The company previously conducted a 1-for-10 reverse stock split in September 2025. The split will reduce the number of outstanding shares significantly.
Read more →LNAILunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
Lunai Bioworks has completed a $20 million preferred equity issuance to acquire CNS delivery and neurotherapeutic intellectual property. This acquisition aims to enhance their capabilities in treating neurological diseases, particularly Alzheimer's, by integrating novel delivery technologies. The company anticipates improved drug development efficiency and potential partnerships, though it faces compliance scrutiny from Nasdaq.
Read more →LNAI▲ +10.1%on this news
Lunai Bioworks, Inc. Announces Postponement of Special Meeting of Stockholders to
Lunai Bioworks, Inc. has announced the postponement of its Special Meeting of Stockholders from May 4, 2026, to May 8, 2026. The delay is intended to provide stockholders additional time to vote and help the company secure a quorum. The Special Meeting will be conducted virtually to facilitate participation. This change was prompted by delays in the distribution of proxy materials affecting broker discretionary voting. Stockholders are encouraged to submit their proxies by the deadline to ensure their votes are cast.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
Lunai Bioworks and Geneial have signed a Letter of Intent to collaborate on building patient cohorts for rare neurological disorders. This partnership aims to convert fragmented patient data into actionable insights for drug development, addressing a significant bottleneck in the industry. Initial programs will integrate datasets from multiple registries to support clinical development and therapeutic programs.
Read more →LNAI▲ +39.8%on this news
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
Lunai Bioworks has announced a revenue-generating collaboration through its subsidiary BioSymetrics, focusing on AI-enabled chemical threat assessment. This multi-year partnership aims to enhance the identification and understanding of neuroactive compounds. The collaboration reflects Lunai's commitment to advancing dual-use technologies in defense and pharmaceutical applications.
Read more →LNAI▲ +22.9%on this news
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications Sacramento, CA
Lunai Bioworks has announced a strategic transaction to acquire blood-brain barrier delivery technology and CNS Alzheimer's drug assets from the Clemann Group for $20 million. This acquisition, structured as Series B Convertible Preferred stock at a fixed conversion price of $1.50 per share, enhances Lunai's pipeline by improving therapeutic delivery to the brain. The new platform is expected to overcome a significant barrier to CNS drug development, allowing for better targeting and activation of therapies specifically in the brain. CEO David Weinstein highlighted the transaction as a transformative step in the company’s capabilities.
Read more →LNAI▲ +22.9%on this news
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications
Lunai Bioworks has announced a $20 million acquisition of blood-brain barrier delivery technology from the Clemann Group. This strategic move aims to enhance its Alzheimer's drug pipeline by improving the delivery of therapeutics to the brain. The fixed conversion price structure strengthens Lunai's equity position while maintaining compliance with NASDAQ regulations. CEO David Weinstein highlighted the acquisition's potential to revolutionize treatment for Alzheimer's and other CNS diseases.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
Lunai Bioworks has launched the Pathfinder Consortium to enhance U.S. chemical defense capabilities against emerging threats. This initiative aims to consolidate fragmented resources into a unified framework, allowing for rapid antidote development within approximately three years. The consortium leverages AI technology and collaboration with leading experts to streamline the process of creating effective countermeasures.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven biotechnology company advancing precision therapeutics in central nervous system (CNS) disorders...
Lunai Bioworks has secured U.S. Patent No. 12,369,861, which focuses on methods for debiasing data in drug discovery. This foundational patent is crucial for their AI-driven platform, enhancing multimodal data standardization and disease stratification. CEO David Weinstein emphasized that this patent is vital for improving biomarker discovery and supports their long-term strategy in precision therapeutics.
Read more →LNAI▼ -10.2%on this news· ran to -29% by day 3shared move
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. Company CEO David Weinstein...
Lunai Bioworks (NASDAQ: LNAI) was featured on CNBC's Business Minute, where CEO David Weinstein discussed the company's AI-driven approach to drug discovery and biodefense. The platform aims to enhance therapeutic development for CNS diseases and improve biodefense preparedness by integrating advanced machine learning and biological datasets. The segment reflects increasing investor interest in AI technologies for healthcare and national security.
Read more →LNAI▲ +24.7%on this news· ran to +60% by day 1
Lunai Bioworks, Inc. Issues Letter to Shareholders Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving forward with several...
Lunai Bioworks, Inc. has completed its AI platform, which is now commercial. The company is negotiating partnerships with pharmaceutical firms to enhance drug discovery processes. Lunai's approach aims to reduce drug development timelines and costs while increasing the probability of success. The company has established three revenue streams focused on AI drug discovery, biodefense, and immunotherapy.
Read more →LNAI▲ +24.7%on this news· ran to +60% by day 1
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced the launch of a new oncology collaboration with a ...
Lunai Bioworks has initiated a collaboration to analyze data from a Phase 2 metastatic colorectal cancer trial using its AI platform. The goal is to identify patient subgroups that may benefit most from the therapy, optimizing trial design and inclusion criteria. This pilot project could expand into a broader program if successful, enhancing patient stratification in clinical trials.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
Lunai Bioworks has launched a new drug discovery program targeting Alcohol Use Disorder (AUD) after achieving significant milestones in its NIH-supported AI initiative. The program aims to develop innovative therapies for a condition affecting around 30 million Americans, with most not receiving effective treatment. The initiative highlights the potential for precision medicine in addressing the complexities of AUD.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons As global attention intensifies around the dual-use risks of advanced artificial intelligence in chemistry and biology, Lunai Bioworks (NASDAQ: LNAI) ...
Lunai Bioworks has launched Sentinel, an AI safeguard designed to prevent the generation of novel chemical agents. This transformer-based biosecurity layer integrates directly into AI systems, utilizing proprietary datasets to detect hazardous molecular designs in real time. The initiative addresses growing concerns over the dual-use risks of AI in chemistry and biology, positioning Lunai at the forefront of AI safety.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under ...
Lunai Bioworks has launched a new drug discovery program targeting Alcohol Use Disorder (AUD) after achieving significant milestones in its NIH-funded AI initiative. The program aims to develop innovative therapies for AUD, which affects around 30 million Americans, with most receiving no effective treatment. The initiative is supported by a STTR grant and aims to address the unmet medical needs in this area.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance Lunai Bioworks Inc. (NASDAQ: LNAI), an AI-driven pharmaceutical discovery company, was featured in International Business Times in a year-end...
Lunai Bioworks Inc. is highlighted in International Business Times for its strategic positioning and active partnership discussions in the CNS sector. The company is negotiating with pharmaceutical firms on programs targeting diseases like Parkinson's and Alzheimer's. Amid a challenging market, Lunai's Augusta platform is recognized for its innovative approach to drug discovery, addressing unmet needs in CNS disorders.
Read more →LNAI▼ -8.7%on this news· ran to -22% by day 3
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three...
Lunai Bioworks has identified three subtypes of Parkinson's disease, which may enhance therapeutic development and strategic partnerships. Utilizing its Augusta Platform, the company integrated extensive proteomic data to uncover these subtypes linked to disease progression. This advancement aims to improve trial success rates and reduce development timelines in a growing market.
Read more →LNAI▼ -15%on this news
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has secured its first Letter of Intent (LOI)...
Lunai Bioworks has secured its first Letter of Intent to license its immune cell therapy, which has shown complete regression of pancreatic tumors in humanized preclinical models. This milestone follows a peer-reviewed publication and a successful pre-IND meeting with the FDA. The company plans to initiate a Phase I clinical trial for its Dendritic Cell Combination Therapy targeting high-need solid tumors.
Read more →LNAI▼ -8.5%on this news
Lunai Bioworks、前臨床のヒト化モデルにおいて、原発および転移性膵臓がんの完全退縮を達成──オールロジェニックがん免疫療法における画期的なブレークスルーを示す AIを活用した創薬およびバイオディフェンス企業である Lunai Bioworks（NASDAQ: LNAI）は、主要な科学的ブレークスルーを発表した。同社の次世代免疫細胞療法により、ヒト化マウスモデルにおいて原発および転移性の膵臓腫瘍が完全退縮したことが確認された。...
Lunai Bioworks has announced significant advancements in its vaccine development, achieving complete remission in a study involving second-generation dendritic cell therapies. The research, published in the journal 'Vaccines', emphasizes the company's innovative use of AI in enhancing treatment efficacy. CEO David Weinstein highlighted the importance of these findings for future clinical applications.
Read more →LNAI▼ -8.5%on this news
Lunai Bioworks schafft es, sowohl primäre als auch metastasierte Bauchspeicheldrüsentumoren in präklinischen humanisierten Modellen komplett zurückzubilden, was einen Durchbruch in der allogenen Krebsimmuntherapie bedeutet Lunai Bioworks (NASDAQ: LNAI), ein KI-gestütztes Unternehmen für Arzneimittelforschung und Bioabwehr, hat einen wichtigen wissenschaftlichen...
Lunai Bioworks has announced a significant breakthrough in cancer immunotherapy, achieving complete regression of both primary and metastatic pancreatic tumors in humanized mouse models. This was made possible through their second-generation dendritic cell therapy platform, which utilizes genetically modified dendritic cells to activate the body's immune system against cancer. The findings were published in the journal 'Vaccines' and are expected to advance ongoing partnership discussions for the therapy.
Read more →LNAI▼ -8.5%on this news
Lunai Bioworks réussit à éliminer complètement les tumeurs pancréatiques primaires et secondaires dans des modèles humanisés précliniques, marquant une avancée significative pour l'immunothérapie allogénique contre le cancer Lunai Bioworks (NASDAQ : LNAI), une entreprise spécialisée dans la découverte de médicaments et la défense biologique utilisant l'intelligence...
Lunai Bioworks has announced a significant breakthrough in cancer immunotherapy, achieving complete regression of both primary and metastatic pancreatic tumors in humanized mouse models. This advancement, published in the journal 'Vaccines', details a second-generation dendritic cell therapy that enhances immune response against cancer. The results pave the way for potential clinical applications and partnerships.
Read more →LNAI▼ -8.5%on this news
Lunai Bioworks logra la regresión completa de tumores pancreáticos primarios y metastásicos Lunai Bioworks (NASDAQ: LNAI), una empresa de descubrimiento de fármacos y biodefensa impulsada por IA ha anunciado un importante avance científico:...
Lunai Bioworks has reported a significant scientific breakthrough with its second-generation dendritic cell therapy, achieving complete regression of primary and metastatic pancreatic tumors in humanized preclinical models. This advancement, published in the journal 'Vaccines', showcases the therapy's potential to activate the immune system against cancer. The findings support ongoing collaborations and clinical applications.
Read more →LNAI▼ -12.8%on this news· ran to -25% by day 3shared move
Lunai Bioworks 在臨床前人源化模型內，實現原發性和轉移性胰臟腫瘤的完全消退，標誌為同種異體癌症免疫療法的突破 Lunai Bioworks（納斯達克股票交易所代號：LNAI）是利用人工智能驅動藥物研發與生物防禦的公司，宣佈重大科學突破：該公司的新一代免疫細胞療法在人源化小鼠模型中，導致原發性和轉移性胰臟腫瘤完全消退。 2025 年 11 月 2...
Lunai Bioworks has announced the development of a new generation of cancer therapies utilizing modified dendritic cells. Their approach aims to enhance tumor-inhibitory functions and potentially lead to tumor regression. The company is leveraging artificial intelligence to innovate in drug development, marking a significant step forward in cancer treatment.
Read more →LNAI▼ -12.8%on this news· ran to -25% by day 3shared move
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthrough: its...
Lunai Bioworks has reported a significant breakthrough in cancer immunotherapy, achieving complete regression of both primary and metastatic pancreatic tumors in humanized mouse models. This advancement stems from their second-generation dendritic cell therapy, which utilizes genetically enhanced immune cells. The findings, published in the journal 'Vaccines', are crucial for future clinical applications and partnerships.
Read more →LNAILunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lunai Bioworks, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, achieving a closing bid price at or above $1.00 for 11 consecutive business days. This compliance enables the company to remain listed on The Nasdaq Capital Market. CEO David Weinstein highlighted this achievement as a testament to their strategic execution and a commitment to shareholder value amid a transformative period for the company. Lunai Bioworks is focused on enhancing its AI-driven capabilities in drug discovery and biodefense.
Read more →LNAIEXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this " Agreement ") is entered into as of [ ], 2025 (the " Effective Date "), by and between Renovaro Inc., a Delaware corporation (the " Company "), and [ ] (the " Holder " an
Renovaro Inc. has entered into an exchange agreement with a Holder to replace secured promissory notes with unsecured convertible notes. This exchange is intended to address the immediate financial obligations associated with the current notes. The new replacement notes will have an increased principal amount and an extended maturity date. This move reflects the company's strategy to manage its debt structure, although it may involve increased financial risks.
Read more →LNAIRenovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, an
Renovaro and BioSymetrics have announced a definitive merger agreement aimed at advancing AI-driven biomarker discovery and precision medicine. The collaboration is set to integrate BioSymetrics' proprietary Elion platform, enhancing Renovaro's capabilities in oncology and drug discovery. This strategic combination is focused on expediting translational research and streamlining the development of effective therapeutics. The merger is expected to close in March 2025, pending regulatory approvals and customary closing conditions.
Read more →LNAIRenovaro to Acquire Predictive Oncology in All-Stock Transaction Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of long
Renovaro Inc. has announced its intention to acquire Predictive Oncology in an all-stock transaction, allowing access to a biobank of over 150,000 tumor specimens and extensive drug response data. This acquisition aims to enhance Renovaro's AI-driven platforms for cancer diagnostics and drug discovery. The combined resources, including Predictive Oncology's multi-omic drug discovery platform, are expected to improve treatment outcomes by helping oncologists tailor therapies for individual patients. The deal reflects a strategic move to increase capabilities in personalized medicine and precision oncology.
Read more →LNAIRenovaro, Inc. Announces $10 million in Equity Committed Los Angeles
Renovaro, Inc. has announced the commitment of $10 million in additional equity, priced at $1.4726 per share, along with 10 percent warrant coverage. The company's CEO, Mark Dybul, highlighted investor confidence and indicated that this investment could be a stepping stone towards securing more substantial financing from various institutions. Renovaro is open to exploring different sources of funding that could total tens of millions of dollars, thereby enhancing its strategic financial positioning.
Read more →LNAIRenovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy Los Angeles, USA and Amsterdam, Netherlands
Renovaro Inc. and Amsterdam UMC Cancer Center have entered into a Memorandum of Understanding to establish a joint company that will focus on developing personalized cancer immunotherapy. The collaboration intends to combine Renovaro's proprietary vaccine technology with the Cancer Center's immunomodulatory expertise to enhance cancer treatment. This new venture will be headquartered in Amsterdam and aims to innovate cancer therapies while improving patient outcomes. Both parties emphasize the need for thorough due diligence before advancing with the project.
Read more →LNAIRenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership Los Angeles and Amsterdam
RenovaroCube has announced its acquisition of 100% ownership of Cyclomics, enhancing their partnership in advanced cancer diagnostics. This move aims to leverage their combined technologies, including Cyclomics' innovative molecular biology techniques and RenovaroCube's AI-driven approach. The collaboration, backed by their relationships with Oxford Nanopore and Nvidia, positions them as leaders in cancer detection and treatment monitoring. This acquisition is expected to significantly improve early detection and personalized treatment for cancer patients.
Read more →Older news (36)
- AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine Los AngelesFeb 13, 2024
- Renovaro Biosciences Announces Results of Special Meeting of Shareholders Los AngelesJan 25, 2024
- Message from Renovaro Bioscience, Inc.'s CEO, The Hon. Mark Dybul, MD Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024Jan 16, 2024
- Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors Los AngelesOct 10, 2023
- AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine Message from Renovaro Biosciences CEO, The Hon. Mark DybulOct 2, 2023
- Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotSep 29, 2023
- Letter of IntentAug 1, 2023
- ENOCHIAN BIOSCIENCES INC. ANNOUNCES ADJOURNMENT OF 2023Jun 23, 2023
- Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA ReviewJun 8, 2023
- Enochian BioSciences' CEO Letter to Shareholders Turning the Page; A Promising Future Los AngelesApr 3, 2023
- Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading ResearcherMar 29, 2023
- Enochian BioSciences Achieves Full Compliance with NASDAQ Filing RequirementsMar 13, 2023
- Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period EndedFeb 23, 2023
- Enochian BioSciences Forges Ahead With Focused Approach, Promising FutureOct 24, 2022
- Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-KOct 21, 2022
- CEO's Letter to Shareholders 06/01/2022 (Updated 09/23/2022) Dear Shareholders: I have spoken to some of you about the serious and disturbing news that broke last week about Serhat Gumrukcu. Enochian's rigorous foundatioSep 23, 2022
- Enochian BioSciences Inc. (NASDAQ: ENOB)Jul 6, 2022
- Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific DataJul 1, 2022
- 01/2022 (Updated 06/06/2022) Dear Shareholders: I have spoken to some of you about the serious and disturbing news that broke last week about Serhat Gumrukcu. Enochian's rigorous foundation is rooted in independently conJun 7, 2022
- Dear Shareholders: I have spoken to some of you about the serious and disturbing news that broke last week about Serhat Gumrukcu. Enochian's rigorous foundation is rooted in independently conducted science, and our commiJun 2, 2022
- Scientific Leaders Agree on Promise of Enochian BioSciences Los AngelesMay 31, 2022
- Enochian BioSciences Board Learns of Arrest of Co-Founder and Inventor and Expresses Strong Confidence in the Promising Future of the Company - The Board learned of the Arrest of Dr. Serhat Gumruk u after the Press ReleaMay 25, 2022
- Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience Los Angeles. April 20,2022. Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciApr 20, 2022
- Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years' Experience at Pfizer Los Angeles.Apr 7, 2022
- Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer SummitApr 5, 2022
- Enochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in HumansMar 15, 2022
- UPDATE Enochian BioSciences: At the Cutting Edge "The future of Biotech is disruptive science from unconventional sources" Dr. Mark Dybul, CEO To: Shareholders of Enochian BioSciences From: The Hon. Dr. Mark Dybul SubjecJan 24, 2022
- Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences' Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza VariantsAug 30, 2021
- Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer Dr. Dybul's Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioScience's Scientific ApproachJul 20, 2021
- Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJun 14, 2021
- Enochian Biosciences Elegant Simplicity: Integrating Diverse Scientific Approaches to Develop Cures Dr. Mark Dybul, Executive Vice Chairman March 9-10, 2021 HC Wainwright Global Life Sciences Conference NASDAQ: ENOB ForwFeb 16, 2021
- SECURITIES AND EXCHANGE COMMISSIONSep 15, 2020
- Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures First presentation of a novel approach to potentially cure HIV - An in vivo study demonstrated a 164 percent increase in engrafMay 13, 2020
- Wolfe Axelrod Weinberger Associates, LLC Stephen D. Axelrod, CFA/Don Weinberger (212) 370-4500, (212) 370-4505 faxApr 5, 2016
- Wolfe Axelrod Weinberger Associates, LLC Stephen D. Axelrod, CFA/Donald C. Weinberger (212) 370-4500, (212) 370-4505 fax steve@wolfeaxelrod.com , don@wolfeaxelrod.com DanDrit Biotech A/S SiSep 30, 2014
- Wolfe Axelrod Weinberger Associates, LLC Stephen D. Axelrod, CFA/Donald C. Weinberger (212) 370-4500, (212) 370-4505 fax steve@wolfeaxelrod.com , don@wolfeaxelrod.com DanDrit Biotech USA, IAug 14, 2014
Competitive Position
How LNAI ranks across every disease it competes inCompetitive Position is a premium feature
See how LNAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial